Berwyn-based Amring Pharmaceuticals, a company providing niche generics and value brands, recently completed its purchase of California-based Visant Medical, a clinical-stage medical device company.
The purchase gives Amring Pharmaceuticals’ parent company, Nordic Group B.V., access to Visant’s FDA-cleared hyaluronic acid derivative LACRIFILL canalicular occlusive device for the temporarily treatment of block tear drainage by the occlusion of the canalicular system.
Nordic Pharma plans to launch and commercialize LACRIFILL in the United States next year. After the U.S. launch, Nordic Pharma will seek regulatory approval to make the product available globally.
“We’re ecstatic Visant Medical selected Nordic Pharma as their partner and for the opportunity to introduce LACRIFILL to the ophthalmologists and optometrists treating the over 16 million people diagnosed with DED (Dry Eye Disease) in the U.S.,” Philip Gioia, president of the team that will launch LACRIFILL under the Nordic Pharma brand, said. “LACRIFILL represents an innovative and elegant form factor to occlude that should become the gold standard for preoperative patient care for those with DED.”
LACRIFILL is used for dry eye conditions and provides relief for the symptoms of dry eye.
Nordic Pharma is an international pharmaceutical company focused on the development and commercialization of specialty products. It is part of SEVER Life Sciences, a holding company.